Royalty Pharma Analyst Ratings
Royalty Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 100.93% | Morgan Stanley | $53 → $54 | Maintains | Overweight |
| 08/09/2023 | 97.21% | Morgan Stanley | $52 → $53 | Maintains | Overweight |
| 07/11/2023 | 93.49% | Morgan Stanley | $52 → $52 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 93.49% | Morgan Stanley | $50 → $52 | Maintains | Overweight |
| 04/10/2023 | 86.05% | Morgan Stanley | $48 → $50 | Maintains | Overweight |
| 04/06/2023 | 123.26% | Tigress Financial | $57 → $60 | Reiterates | → Buy |
| 02/16/2023 | 78.6% | UBS | $51 → $48 | Maintains | Buy |
| 12/06/2022 | 89.77% | Morgan Stanley | $54 → $51 | Maintains | Overweight |
| 11/09/2022 | 100.93% | Morgan Stanley | $51 → $54 | Maintains | Overweight |
| 10/18/2022 | 93.49% | JP Morgan | $50 → $52 | Maintains | Overweight |
| 08/08/2022 | 89.77% | Morgan Stanley | $48 → $51 | Maintains | Overweight |
| 07/14/2022 | 112.09% | Tigress Financial | $52 → $57 | Maintains | Buy |
| 06/14/2022 | 74.88% | UBS | → $47 | Initiates Coverage On | → Buy |
| 05/13/2022 | 97.21% | Scotiabank | → $53 | Initiates Coverage On | → Outperform |
| 04/27/2022 | 108.37% | Goldman Sachs | → $56 | Initiates Coverage On | → Buy |
| 04/14/2022 | 86.05% | JP Morgan | → $50 | Upgrades | Neutral → Overweight |
| 04/06/2022 | 78.6% | Morgan Stanley | $46 → $48 | Upgrades | Equal-Weight → Overweight |
| 10/29/2021 | 86.05% | Citigroup | → $50 | Upgrades | Neutral → Buy |
| 08/16/2021 | 71.16% | Morgan Stanley | $51 → $46 | Maintains | Equal-Weight |
| 07/30/2021 | 86.05% | Tigress Financial | → $50 | Initiates Coverage On | → Buy |
| 11/09/2020 | 89.77% | UBS | → $51 | Upgrades | Neutral → Buy |
| 07/13/2020 | 86.05% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/13/2020 | 104.65% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 07/13/2020 | 89.77% | Morgan Stanley | → $51 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 104.65% | Cowen & Co. | → $55 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 108.37% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 11 月 10 日 | 100.93% | 摩根士丹利 | 53 美元 → 54 美元 | 維護 | 超重 |
| 08/09/2023 | 97.21% | 摩根士丹利 | 52 美元 → 53 美元 | 維護 | 超重 |
| 07/11/2023 | 93.49% | 摩根士丹利 | 52 美元 → 52 美元 | 重申 | 超重 → 超重 |
| 05/10/2023 | 93.49% | 摩根士丹利 | 50 美元 → 52 美元 | 維護 | 超重 |
| 2023 年 10 月 4 日 | 86.05% | 摩根士丹利 | 48 美元 → 50 美元 | 維護 | 超重 |
| 04/06/2023 | 123.26% | 泰格雷斯金融 | 57 美元 → 60 美元 | 重申 | → 購買 |
| 02/16/2023 | 78.6% | 瑞銀（UBS） | 51 美元 → 48 美元 | 維護 | 購買 |
| 12/06/2022 | 89.77% | 摩根士丹利 | 54 美元 → 51 美元 | 維護 | 超重 |
| 11/09/2022 | 100.93% | 摩根士丹利 | 51 美元 → 54 美元 | 維護 | 超重 |
| 2022 年 10 月 18 日 | 93.49% | 摩根大通 | 50 美元 → 52 美元 | 維護 | 超重 |
| 08/08/2022 | 89.77% | 摩根士丹利 | 48 美元 → 51 美元 | 維護 | 超重 |
| 07/14/2022 | 112.09% | 泰格雷斯金融 | 52 美元 → 57 美元 | 維護 | 購買 |
| 06/14/2022 | 74.88% | 瑞銀（UBS） | → 47 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/13/2022 | 97.21% | 豐業銀行 | → 53 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 04/27/2022 | 108.37% | 高盛 | → 56 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 4 月 14 日 | 86.05% | 摩根大通 | → 50 美元 | 升級 | 中性 → 超重 |
| 04/06/2022 | 78.6% | 摩根士丹利 | 46 美元 → 48 美元 | 升級 | 重量相等 → 超重 |
| 10/29/2021 | 86.05% | 花旗集團 | → 50 美元 | 升級 | 中性 → 買入 |
| 2021 年 8 月 16 日 | 71.16% | 摩根士丹利 | 51 美元 → 46 美元 | 維護 | 重量相等 |
| 07/30/2021 | 86.05% | 泰格雷斯金融 | → 50 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/09/2020 | 89.77% | 瑞銀（UBS） | → 51 美元 | 升級 | 中性 → 買入 |
| 07/13/2020 | 86.05% | 摩根大通 | → 50 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 07/13/2020 | 104.65% | B of A 類證券 | → 55 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/13/2020 | 89.77% | 摩根士丹利 | → 51 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 07/13/2020 | 104.65% | Cowen & Co. | → 55 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 07/13/2020 | 108.37% | SunTrust 羅賓遜·漢弗萊 | → 56 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的目標價格是多少？
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by Morgan Stanley on October 11, 2023. The analyst firm set a price target for $54.00 expecting RPRX to rise to within 12 months (a possible 100.93% upside). 10 analyst firms have reported ratings in the last year.
摩根士丹利於2023年10月11日公佈了Royalty Pharma（納斯達克股票代碼：RPRX）的最新目標股價。該分析公司將目標股價定爲54.00美元，預計RPRX將在12個月內升至12個月內（可能上漲100.93％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的最新分析師評級是多少？
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by Morgan Stanley, and Royalty Pharma maintained their overweight rating.
Royalty Pharma（納斯達克股票代碼：RPRX）的最新分析師評級由摩根士丹利提供，Royalty Pharma維持其增持評級。
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Royalty Pharma的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Royalty Pharma的最後一次評級是在2023年10月11日提交的，因此你應該預計下一個評級將在2024年10月11日左右公佈。
Is the Analyst Rating Royalty Pharma (RPRX) correct?
分析師對Royalty Pharma（RPRX）的評級是否正確？
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $53.00 to $54.00. The current price Royalty Pharma (RPRX) is trading at is $26.88, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的特許權使用費製藥（RPRX）評級保持不變，目標價爲53.00美元至54.00美元。Royalty Pharma（RPRX）目前的交易價格爲26.88美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。